BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34505914)

  • 1. Novel EBV LMP1 C-terminal domain binding affibody molecules as potential agents for in vivo molecular imaging diagnosis of nasopharyngeal carcinoma.
    Kamara S; Guo Y; Mao S; Ye X; Li Q; Zheng M; Zhu J; Zhang J; Du W; Chen J; Zhu S; Zhang L
    Appl Microbiol Biotechnol; 2021 Oct; 105(19):7283-7293. PubMed ID: 34505914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models.
    Guo Y; Kamara S; Zhang J; Wen H; Zheng M; Liu Y; Zhou L; Chen J; Zhu S; Zhang L
    Front Cell Infect Microbiol; 2022; 12():1078504. PubMed ID: 36683690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells.
    Zhu J; Kamara S; Cen D; Tang W; Gu M; Ci X; Chen J; Wang L; Zhu S; Jiang P; Chen S; Xue X; Zhang L
    Cell Death Dis; 2020 Apr; 11(4):213. PubMed ID: 32238802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma.
    Kamara S; Guo Y; Wen H; Liu Y; Liu L; Zheng M; Zhang J; Zhou L; Chen J; Zhu S; Zhang L
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
    Wasil LR; Wei L; Chang C; Lan L; Shair KH
    J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
    Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
    Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma.
    Zhu S; Chen J; Xiong Y; Kamara S; Gu M; Tang W; Chen S; Dong H; Xue X; Zheng ZM; Zhang L
    PLoS Pathog; 2020 Jan; 16(1):e1008223. PubMed ID: 31905218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
    Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
    J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis.
    Shi F; He Y; Li J; Tang M; Li Y; Xie L; Zhao L; Hu J; Luo X; Zhou M; Liu N; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Jia W; Bode AM; Cao Y
    Mol Metab; 2020 Jun; 36():100966. PubMed ID: 32224436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma.
    Verhoeven RJ; Tong S; Zhang G; Zong J; Chen Y; Jin DY; Chen MR; Pan J; Chen H
    J Virol; 2016 Jul; 90(14):6475-88. PubMed ID: 27147748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical study of LMP1-RNAi-based anti-tumor therapy in EBV-positive nasopharyngeal carcinoma.
    Yuan Q; Chen BH; Huang DJ; Zhang R
    Braz J Med Biol Res; 2023; 56():e12638. PubMed ID: 37493769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Epstein-Barr virus-encoded latent membrane protein (LMP-1), p16 and p53 proteins in nonendemic nasopharyngeal carcinoma (NPC): a clinicopathological study.
    Rosales-Pérez S; Cano-Valdez AM; Flores-Balcázar CH; Guedea-Edo F; Lino-Silva LS; Lozano-Borbalas A; Navarro-Martín A; Poitevin-Chacón A
    Arch Med Res; 2014 Apr; 45(3):229-36. PubMed ID: 24606815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance.
    Xie L; Shi F; Li Y; Li W; Yu X; Zhao L; Zhou M; Hu J; Luo X; Tang M; Fan J; Zhou J; Gao Q; Wu W; Zhang X; Liao W; Bode AM; Cao Y
    Signal Transduct Target Ther; 2020 May; 5(1):56. PubMed ID: 32433544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.
    Lin MC; Lin YC; Chen ST; Young TH; Lou PJ
    BMC Cancer; 2017 Jan; 17(1):18. PubMed ID: 28056887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of ATOH8 induced by EBV-encoded LMP1 contributes to the malignant phenotype of nasopharyngeal carcinoma.
    Wang Z; Xie J; Yan M; Wang J; Wang X; Zhang J; Zhang Y; Li P; Lei X; Huang Q; Lin S; Guo X; Liu Q
    Oncotarget; 2016 May; 7(18):26765-79. PubMed ID: 27049918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules.
    Liu Y; Lui KS; Ye Z; Fung TY; Chen L; Sit PY; Leung CY; Mak NK; Wong KL; Lung HL; Tanaka Y; Cheung AKL
    Theranostics; 2023; 13(2):458-471. PubMed ID: 36632221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.
    Brooks L; Yao QY; Rickinson AB; Young LS
    J Virol; 1992 May; 66(5):2689-97. PubMed ID: 1313894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway.
    Yang CF; Peng LX; Huang TJ; Yang GD; Chu QQ; Liang YY; Cao X; Xie P; Zheng LS; Huang HB; Cai MD; Huang JL; Liu RY; Zhu ZY; Qian CN; Huang BJ
    Cancer Lett; 2014 Mar; 344(2):260-71. PubMed ID: 24262659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insufficient PINX1 expression stimulates telomerase activation by direct inhibition of EBV LMP1-NF-κB axis during nasopharyngeal carcinoma development.
    Liu Y; Gong P; Zhou N; Zhang J; He C; Wang S; Peng H
    Biochem Biophys Res Commun; 2019 Jun; 514(1):127-133. PubMed ID: 31027734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV-LMP1-targeted DNAzyme restrains nasopharyngeal carcinoma growth in a mouse C666-1 xenograft model.
    Ke X; Yang YC; Hong SL
    Med Oncol; 2011 Dec; 28 Suppl 1():S326-32. PubMed ID: 20862567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.